ShanZeBIO

Cambridge, United Kingdom and Shanghai, China, October 28, 2026 – Mundipharma and ShanZeBIO today announced that parties have entered into a strategic licensing agreement for REZZAYO® / XIUNIS® (rezafungin acetate) in Mainland China, Hong Kong and Macau. This agreement will support access to REZZAYO® / XIUNIS® for eligible patients across the region. Under the agreement, ShanZeBIO holds the exclusive licence to register, develop and commercialise REZZAYO® / XIUNIS® in Mainland China, Hong Kong and Macau and will lead commercialisation across the region with an experienced team of anti-infectives specialists. “This strategic licensing arrangement reflects our commitment to expanding access to innovative medicines where they can make a meaningful difference for patients,” said Marc Princen, CEO, Mundipharma. “ShanZeBIO brings deep local expertise, a dedicated anti-infectives strategy and the commercial capabilities to support REZZAYO® / XIUNIS® across the region. Together, we believe this collaboration can help ensure appropriate patients have access to an important treatment option while allowing Mundipharma to maintain focus on our strategic priorities in China.” “This partnership with Mundipharma reflects a shared commitment to addressing unmet medical needs in anti-infectives in Mainland China, Hong Kong and Macau,” said Jin Xiaodong, CEO, ShanZeBIO. “Our medical expertise and proven commercial capabilities position us to deliver the full value of REZZAYO® / XIUNIS® to patients

The partnership will support the continued availability of Avelox® across Asia-Pacific, the Middle East, Africa and Europe through Clinigen’s international commercial and distribution infrastructure. SINGAPORE, 23 September 2026 – Clinigen, a global speciality pharmaceutical services company, and ShanZeBIO, a specialised platform company dedicated to the acquisition, introduction and commercialisation of innovative pharmaceutical products, today announced an exclusive commercialisation and distribution partnership for Avelox® (moxifloxacin) across 16 international markets spanning Asia-Pacific, the Middle East, Africa and Europe. Under the agreement, Clinigen will be responsible for the commercialisation and distribution of Avelox® in the agreed territories, drawing on its capabilities across regulatory affairs, supply chain management, commercial operations and speciality pharmaceutical distribution. ShanZeBIO will provide product supply and pharmaceutical expertise to support implementation of the partnership. The agreement reflects the important role that specialised commercial and distribution partners can play in supporting the long-term availability of established medicines. While many products continue to be relied upon by healthcare systems years after their initial launch, maintaining their presence across geographically diverse markets requires ongoing commercial support, regulatory oversight and supply-chain infrastructure. By combining ShanZeBIO’s pharmaceutical expertise with Clinigen’s international platform and market knowledge, the companies will work together to support the continued availability of Avelox®

September 3, 2026, Shanghai – ShanZeBIO today officially announced that, through close collaboration with Clinigen, a leading global pharmaceutical services provider, it has successfully obtained the Marketing Authorization (MA) for Avelox in Singapore. This is the first MA transfer for ShanZeBIO since it reached an agreement with Bayer on the global rights to Avelox this February, marking the company’s official acquisition of full and independent rights to the product, and the full-scale launch of Avelox’s global operations with innovator quality and standards. ShanZeBIO is a specialized platform company invested by HSG and dedicated to the acquisition, introduction and commercialization of innovative pharmaceutical products from around the world. From rights transfer to the completion of the first overseas market access, the company took only half a year, fully demonstrating ShanZeBIO’s comprehensive capabilities in rapid market access, full product lifecycle management, and global operations. This MA transfer in Singapore also marks a significant milestone for ShanZeBIO in its independent operation and internationalization strategy for Avelox – formally gaining autonomous management control over the entire process from manufacturing and logistics to distribution, ensuring uniform global product management with high-standard quality systems, and setting a benchmark for the company’s future in-licensing and operation of more global